Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Company Overview - Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients [5] - The company's advanced programs include treatments for hemophilia, narcolepsy, and immuno-oncology utilizing the LockBody® technology platform [5] Public Offering Details - Centessa Pharmaceuticals has announced a public offering of $150 million of American Depositary Shares (ADSs), each representing one ordinary share [1] - The company plans to grant underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs [1] - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1] Underwriters - Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the offering [2]